The Antidiarrheal Efficacy of a Proprietary Amino Acid Mixture (enterade®) in Neuroendocrine Tumor (NETs) Patients.

Aman Chauhan1,2, Rachel C Miller2, Gian Yu3, Laura P Luque4, Lowell Brian Anthony1,2
1 Department of Internal Medicine, Division of Medical Oncology, Markey Cancer Center, University of Kentucky Lexington, KY; 2 Dietitian Consultant Markey Cancer Center; 3 University of Kentucky School of Medicine; 4 Entrinsic Health Solutions Inc.

INTRODUCTION

Based on SEER database, gastroenteropancreatic neuroendocrine tumor (GEPNET) incidence has increased 6-fold over past 3 decades.

We conducted a retrospective chart review to evaluate antidiarrheal efficacy of enterade® in neuroendocrine tumor patients with quality of life limiting diarrhea.

METHODS

Medical records of all the GEPNET patients treated with enterade® for symptomatic diarrhea were evaluated.

Patients were treated at Markey Cancer Center between May 2017–June 2018.

DEMOGRAPHICS/RESULTS

• A total of 69 patients were given enterade®, enterade® was administered as an 8oz bottle BID for 1 week.
• Antidiarrheal efficacy data was available on 41 patients.
• 15 patients had small bowel neuroendocrine tumors (NET), 5 had bronchial NETs, 2 had colorectal NETs, 3 had NETs of unknown primary, 3 had gastric NETs, 3 had pancreatic NETs and one was high grade neuroendocrine carcinoma of prostate.
• 21 patients had history of prior bowel resection either for primary neuroendocrine tumor resection or debulking.
• 25 patients were on somatostatin analogs at the time of initiation of enterade®.

RESULT/CONCLUSIONS

• 33 out of 41 (80%) patients reported subjective improvement in diarrhea symptoms (Table 1)
• 51% (21/41) reported more than 50% reduction in diarrhea frequency.
• A prospective Phase II study (NCT03722511) of enterade in neuroendocrine tumor patients with quality of life limiting diarrhea is starting Q4 2018.